Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with en...
Автор: ecancer
Загружено: 2026-02-05
Просмотров: 4
Описание:
Dr Geoffrey Liu talks to ecancer about data he presented at ESMO 2025.
The TRUST-II global phase II study evaluated taletrectinib, a next-generation, CNS-active ROS1 inhibitor, in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who had previously been treated with entrectinib.
Among 10 entrectinib-pretreated patients, taletrectinib achieved a systemic objective response rate (ORR) of 80% and an intracranial ORR of 50%, showing strong activity even after prior ROS1 TKI therapy. Some patients maintained clinical benefit beyond radiographic progression.
The safety profile was consistent with prior findings; most common adverse events were elevated liver enzymes and gastrointestinal symptoms, generally manageable with dose adjustments. No treatment-related discontinuations or deaths occurred.
Dr Liu notes that taletrectinib demonstrated promising efficacy and tolerability as a second-line treatment for entrectinib-pretreated ROS1+ NSCLC, supporting its potential role in managing this patient population.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
